Chinmay Jani, Chief Fellow, Hematology and Oncology at Sylvester Comprehensive Cancer Center at University of Miami, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Excited to share our recent work on Bispecifics
Under the guidance of Aakash Desai, we analyzed the rapidly expanding landscape of bispecific antibodies (BsAbs) in solid tumors using the LARVOL CLIN database. We identified 681 clinical trials evaluating 183 BsAbs, a number that has doubled since 2019, with a strong focus on immune checkpoint bispecifics (PD1–CTLA4, PD1–VEGF) and emerging oncogene targets such as EGFR–MET, particularly in lung and GI cancers.
As I embark on my journey as a Thoracic Oncologist with a particular focus on Phase 1 and early drug development, this work reflects how novel immunotherapies are reshaping solid tumor oncology.
This work complements other review articles from this year, where I explored:
• Cancer vaccines and Oncolytic viruses in Solid Oncology:
• Immunotherapy combinations, including strategies incorporating gut microbiome modulators:
Immunotherapy remains a constantly evolving field in Precision Oncology, and early-phase trials are where many of these transformative ideas first reach patients. Looking forward to continuing to contribute to this space through translational research and clinical trials.”
Title: The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
Authors: Rafik ElBeblawy, Chinmay Jani, Judith Pérez-Granado, Mark Gramling, Aakash Desai
Read the Full Article on Cancer Medicine
More posts featuring Chinmay Jani.